首页> 外文期刊>Cell chemical biology >Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1
【24h】

Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1

机译:氯环嗪通过直接靶向HCV包膜糖蛋白1来抑制丙型肝炎病毒进入的病毒融合

获取原文
获取原文并翻译 | 示例
           

摘要

Chlorcyclizine (CCZ) is a potent hepatitis C virus (HCV) entry inhibitor, but its molecular mechanism is unknown. Here, we show that CCZ directly targets the fusion peptide of HCV E1 and interferes with the fusion process. Generation of CCZ resistance-associated substitutions of HCVin?vitrorevealed six missense mutations in the HCV E1 protein, five being in the putative fusion peptide. A viral fusion assay demonstrated that CCZ blocked HCV entry at the membrane fusion step and that the mutant viruses acquired resistance to CCZ's action in blocking membrane fusion. UV cross-linking of photoactivatable CCZ-diazirine-biotin in both HCV-infected cells and recombinant HCV E1/E2 protein demonstrated direct binding to HCV E1 glycoprotein. Mass spectrometry analysis revealed that CCZ cross-linked to an E1 sequence adjacent to the putative fusion peptide. Docking simulations demonstrate a putative binding model, wherein CCZ binds to a hydrophobic pocket of HCV E1 and forms extensive interactions with the fusion peptide.
机译:氯环(CCZ)是一种有效的丙型肝炎病毒(HCV)进入抑制剂,但其分子机制是未知的。在这里,我们表明CCZ直接针对HCV E1的融合肽并干扰融合过程。产生CCZ抗性相关替代的HCVIN?VITROREVELED在HCV E1蛋白中的六个畸形突变,五个处于推定融合肽中。病毒融合测定证明CCZ封闭在膜融合步骤中的HCV进入,突变病毒在阻断膜融合中获得了对CCZ的作用的抗性。 HCV感染细胞和重组HCV E1 / E2蛋白在HCV感染细胞和重组HCV E1 / E2蛋白中的紫外线交联 - 生物素显示与HCV E1糖蛋白直接结合。质谱分析显示CCZ交联与推定融合肽相邻的E1序列。对接模拟证明了一种推定的结合模型,其中CCZ与HCV E1的疏水袋结合,形成与融合肽的广泛相互作用。

著录项

  • 来源
    《Cell chemical biology》 |2020年第7期|共18页
  • 作者单位

    Liver Diseases Branch National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health;

    Liver Diseases Branch National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health;

    Division of Pre-Clinical Innovations National Center for Advancing Translational Sciences National Institutes of Health;

    Liver Diseases Branch National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health;

    Liver Diseases Branch National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health;

    Liver Diseases Branch National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health;

    Li Ka Shing Virology Institute University of Alberta;

    Division of Pre-Clinical Innovations National Center for Advancing Translational Sciences National Institutes of Health;

    Advanced Mass Spectrometry Facility National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health;

    Division of Pre-Clinical Innovations National Center for Advancing Translational Sciences National Institutes of Health;

    Advanced Mass Spectrometry Facility National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health;

    Division of Pre-Clinical Innovations National Center for Advancing Translational Sciences National Institutes of Health;

    Liver Diseases Branch National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 普通生物学;生物化学;
  • 关键词

    viral infection; fusion peptide; drug resistance-associated substitutions; photo-activated cross-linking; membrane fusion; molecular modeling; viral hepatitis; antiviral development; vaccine;

    机译:病毒感染;融合肽;药物抵抗相关的取代;光活性交联;膜融合;分子建模;病毒性肝炎;抗病毒发育;疫苗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号